Cue Biopharma, Inc. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 96/100
What the filing says
On July 9, 2026, Cue Biopharma announced a $50.0 million private placement: 1,418,071 shares at $33.21/share plus pre-funded warrants to purchase 87,500 shares at $33.209/warrant (exercise price $0.001). Led by Cormorant Asset Management with Columbia Threadneedle Investments participating. Expected close ~July 13, 2026. Proceeds designated for clinical development and general corporate purposes.
Why this rating
At $52M market cap, a $50M capital raise is nearly equal to company size—transformational for a clinical-stage biotech. Extends runway materially; high-quality investor group signals confidence. Business-changing financing event.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.